Split face comparison between common concentration vs double dilution of intradermal abobotulinum toxin type A (Dysport) injection for facial lifting in Asians

J Cosmet Dermatol. 2018 Jun;17(3):355-360. doi: 10.1111/jocd.12667.

Abstract

Background: The most efficacious concentration of botulinum toxin for facial lifting is not well established.

Objective: This study compared the efficacy of common concentration vs double dilution of intradermal abobotulinum toxin type A (Dysport) injection for facial lifting in Asians.

Methods: In all, 10 women aged 32-61 years with mild to moderate facial laxity participated in this study. Each patient received one session of intradermal injection of double diluted abobotulinum toxin type A (Dysport) (dilution of 15 mL to give 3.33 units per 0.1 mL) on one side of the face and common concentration (dilution of 7.5 mL to give 6.67 units per 0.1 mL) on the opposite side of the face. Clinical improvement of facial lifting, wrinkling, and subjective satisfaction was evaluated at every visit (baseline, 2, 4, 8, and 12 weeks).

Results: Both concentrations offered reduction of facial laxity and wrinkles, with no statistical difference. The effects gradually increased and lasted for a minimum 12 weeks with both concentrations.

Conclusion: Common concentration and double dilution of intradermal abobotulinum toxin type A (Dysport) injection were effective and safe for facial lifting in Asians. There were no statistically significant differences between the two concentrations.

Keywords: botulinum toxin; facial lifting; facial sagging; intradermal abobotulinum toxin type A.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Acetylcholine Release Inhibitors / administration & dosage*
  • Adult
  • Asian People
  • Botulinum Toxins, Type A / administration & dosage*
  • Double-Blind Method
  • Female
  • Humans
  • Middle Aged
  • Patient Satisfaction
  • Pilot Projects
  • Rhytidoplasty / methods
  • Skin Aging*
  • Treatment Outcome

Substances

  • Acetylcholine Release Inhibitors
  • Botulinum Toxins, Type A
  • abobotulinumtoxinA